OPINION:
Since President Donald Trump returned to office, his Administration has made strengthening our national security a priority. Congress must do its part to ensure America is prepared for biological threats. As a physician and an Army veteran, I know that readiness requires sustained investment and planning before a crisis strikes. That is why I am calling for a multi-year reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) before the current extension expires on Dec. 31. We must give our hospitals, researchers, and health officials the tools they need to protect the American people.
PAHPA is the backbone of America’s health emergency preparedness, underpinning everything from the Strategic National Stockpile (SNS) to the development of critical medical countermeasures. Congress first passed it two decades ago and built in expiration dates so lawmakers would regularly revisit and strengthen it. Since most of the law lapsed in 2023, Congress has relied on short-term extensions that make serious, long-term crisis preparation nearly impossible.
PAHPA has delivered real results. The law created the Biomedical Advanced Research and Development Authority (BARDA), the federal hub for developing and buying medical countermeasures needed to address biological, radiological, and nuclear threats, pandemic influenza, and emerging infectious diseases. Products BARDA has backed have earned 116 Food and Drug Administration (FDA) approvals, licensures and clearances to date.
People were interested in these podcasts
PAHPA’s investments have paid off. Working with industry through Project BioShield, which PAHPA reauthorizations have funded, BARDA has helped add 23 products to the Strategic National Stockpile to counter threats ranging from anthrax and smallpox to nerve agents and radiation exposure. When Ebola and Zika outbreaks hit, BARDA supported critical medical countermeasures and diagnostic technologies. And when COVID-19 emerged, a decade of investment in medical countermeasure research and development enabled BARDA to respond quickly, issuing its first pandemic awards in early 2020.
PAHPA also authorizes the Hospital Preparedness Program, which helps hospitals keep their doors open and restore services during disasters. Through the regional health care coalitions it supports, nearly every acute care hospital in the country now plans for emergencies alongside public health and emergency management agencies.
But those gains are at risk if Congress keeps running PAHPA on short-term extensions.
America’s adversaries are investing in exactly the capabilities PAHPA exists to counter. The State Department’s most recent compliance report concluded that Iran has not abandoned its intention to research and develop biological agents and toxins for offensive purposes, and that it retains the flexibility to turn legitimate research into lethal biological weapons agents whenever its leadership gives the order. The Office of the Director of National Intelligence (ODNI) has reached a similar conclusion.
A weakened health security system is a national security vulnerability. Developing and maintaining the medical countermeasures, diagnostic tools and response capabilities needed to address biological threats requires time and investment. Companies will not make that investment against authorities that expire every few months. Short-term extensions keep the lights on; they do not build capability. The solution is a multi-year PAHPA reauthorization.
As a physician, a veteran and a member of Congress, I know that protecting Americans requires us to prepare before a crisis strikes. That means listening to the hospitals, researchers and state and local officials who put these programs to work and making sure we are investing in what delivers results. PAHPA is an opportunity to strengthen that readiness, modernize our defenses, and ensure taxpayer dollars support the capabilities we need to keep Americans safe.
We cannot wait until an emergency to build a stockpile, develop a vaccine or prepare our hospitals to care for a surge of patients. These capabilities take years to develop, and our adversaries will not wait for Congress to get its work done. With the current extension expiring Dec. 31, Congress must pass a multi-year reauthorization. Protecting the American people is our first responsibility. We need to act now.
• An Army veteran and physician from Panama City, Congressman Neal Dunn proudly represents the Second Congressional District of Florida. He serves as vice chair on the House Committee on Energy & Commerce and is a member on the Select Committee on China.

Please read our comment policy before commenting.